Oxalys Pharmaceuticals

Oxalys Pharmaceuticals is developing innovative new drugs to halt, slow, or reverse the course of neurodegenerative diseases. The Oxalys lead therapeutic is on track for a Phase I/II clinical trial and was granted orphan drug status by the FDA. It is positioned to become the first disease-modifying therapeutic for Huntington’s disease. The company also has a Parkinson’s disease preclinical program that has been co-funded by the Michael J Fox Foundation and NRC IRAP.